6.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
Astria Therapeutics Inc. Stock Analysis and ForecastFree Stock Index Interpretation - PrintWeekIndia
What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional
What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
Published on: 2025-07-19 19:06:02 - jammulinksnews.com
Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser
why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - beatles.ru
What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru
Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha
Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace
Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):